Contact our responsive and friendly client services team any time.
(03) 9028 2888
clients@freshequities.com
Current price
▾0.003 (0.55%)
Last trade: Invalid date GMT
Market cap
20 min delay
Immutep Limited are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S. They are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by their Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. Their objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. They have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Level 12/95 Pitt St, Sydney NSW 2000, Australia
Filter
Announcement | T+2 Movement | Date |
---|---|---|
Day
3m
1yr
5yr
Current price
-
Open price
-
Day low-high
-
Price change
Percent change
Previous close
-
Volume
-
Turnover
-
Bid price
-
Ask price
-
Market cap
-
Shares outstanding
-
Year high
-
Year low
-
Year low-high
-
Earnings per share
-
Price/earnings ratio
-
Dividend yield
-
Dividend per share
-
Franking
-
Company | Market Cap | ||
---|---|---|---|
Live Chat
(03) 9028 2888
clients@freshequities.com
Level 19, 15 William St
Melbourne VIC 3000
Australia